Back to Search
Start Over
A real-world analysis of roxadustat effectiveness and safety in managing renal anemia among patients on maintenance hemodialysis: An observational study.
- Source :
-
Medicine [Medicine (Baltimore)] 2024 Aug 02; Vol. 103 (31), pp. e39203. - Publication Year :
- 2024
-
Abstract
- We aimed to compare the clinical efficacy and safety of roxadustat with erythropoiesis-stimulating agents, particularly erythropoietin (EPO), in the treatment of maintenance hemodialysis patients with renal anemia. A prospective cohort study was carried out at the Nephrology Department of the Nantong First People's Hospital and Nantong University Affiliated Hospital from December 2020 to December 2021. We compared hemoglobin (Hb) levels, serum ferritin (SF) levels, and adverse cardiovascular events between the roxadustat and EPO groups at 1, 3, and 6 months into the treatment. A total of 209 patients participated in the study, with 112 in the roxadustat group and 97 in the EPO group. At baseline, no statistically significant differences were observed between the 2 groups in terms of age, gender, weight, dialysis modality and duration, previous EPO dosage, Hb levels, SF levels, transferrin saturation, heart function classification, and blood pressure levels (P > .05). After 1 month, Hb levels in the roxadustat group were significantly higher than those in the EPO group (P < .05). However, no statistically significant differences were found between the 2 groups at 3 and 6 months (P > .05). Additionally, there were no significant differences in SF levels and the occurrence of adverse cardiovascular events between the 2 groups after treatment (P > .05). Roxadustat was superior to EPO in the initial treatment phase, while its cardiovascular safety was comparable to that of EPO.<br />Competing Interests: The authors have no conflicts of interest to disclose.<br /> (Copyright © 2024 the Author(s). Published by Wolters Kluwer Health, Inc.)
- Subjects :
- Humans
Male
Female
Middle Aged
Prospective Studies
Aged
Erythropoietin therapeutic use
Hematinics therapeutic use
Hematinics adverse effects
Hematinics administration & dosage
Glycine analogs & derivatives
Glycine therapeutic use
Ferritins blood
Treatment Outcome
Renal Dialysis adverse effects
Anemia drug therapy
Anemia etiology
Isoquinolines therapeutic use
Isoquinolines adverse effects
Isoquinolines administration & dosage
Hemoglobins analysis
Hemoglobins metabolism
Subjects
Details
- Language :
- English
- ISSN :
- 1536-5964
- Volume :
- 103
- Issue :
- 31
- Database :
- MEDLINE
- Journal :
- Medicine
- Publication Type :
- Academic Journal
- Accession number :
- 39093766
- Full Text :
- https://doi.org/10.1097/MD.0000000000039203